Literature DB >> 17552122

HIV and hepatitis C virus coinfection, Cameroon.

Christian Laurent, Anke Bourgeois, Mireille Mpoudi, Christelle Butel, Eitel Mpoudi-Ngolé, Eric Delaporte.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17552122      PMCID: PMC2725885          DOI: 10.3201/eid1303.061069

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


× No keyword cloud information.
To the Editor: Coinfection with HIV and hepatitis C virus (HCV) is now a major public health concern worldwide, owing both to its high prevalence (4–5 million persons of 40 million infected by HIV) and to interactions between the 2 diseases in terms of their diagnosis, natural course, and treatment (,). Although Africa is the continent by far the most badly affected by both HIV and HCV infections, data on coinfection in the general population are lacking. In Cameroon, a central African country, the HCV seroprevalence is among the highest in the world (13.8%) (). We have also reported a high seroprevalence of HIV in a general population of southern Cameroon (7.4%), and especially in young women (22.5%) (). Here, we investigated the prevalence of HIV/HCV coinfection in this population. A population-based, cross-sectional survey was conducted in September 2001 in 3 villages of the East Province of Cameroon (250 km from Yaoundé, the capital city). The study methods, the baseline characteristics of the participants, and the HIV seroprevalence have been described in detail elsewhere (). Briefly, all inhabitants >15 years of age were eligible for the survey. After giving their informed consent, the participants were interviewed by using a standard verbal questionnaire, in French or in a local language, during door-to-door visits. Blood samples were collected by peripheral venipuncture, and serum was screened for antibodies to HCV by using an enzyme immunoassay (INNOTEST HCV Ab IV, Innogenetics, Ghent, Belgium). Samples with indeterminate results were retested. All positive and twice-indeterminate samples were confirmed with a third-generation line immunoassay (INNO-LIA HCV Ab III update, Innogenetics). Serologic screening for HIV infection was based on an enzyme immunoassay (Murex HIV-1.2.O, Abbott, Rungis, France). All positive samples were confirmed by using a line immunoassay (INNO-LIA HIV-1+2, Innogenetics). Among the 484 participants, 256 were women (52.9%), and the median age was 34 years (interquartile range 23–52 years). Most participants (93.6%) were Bantus; the remainder were pygmies. Seven persons refused venipuncture after the interview, and 1 sample could not be analyzed. These 8 persons did not differ from the rest of the study population in term of sex (50.0% women vs. 47.1% women), but they were slightly younger (median, 26.8 years vs. 34.9 years). Of the 476 available samples, respectively 19 (4.0%) had indeterminate HCV serologic results, and 5 (1.1%) had indeterminate HIV serologic results. The overall seroprevalence rates were 21.0% (95% confidence interval [CI] 17.4%–24.9%) for HCV and 7.4% (95% CI 5.2%–10.1%) for HIV. Only 3 patients (0.6%) had positive results for both infections: a man 29 years of age and 2 women ages 36 and 52 years. The Figure shows the seroprevalence rates of HCV and HIV according to sex and age. Multivariate random-effects logistic regression analyses showed different risk factors for the 2 infections. The HCV seroprevalence was associated with age (<45 vs. ≥45 years, odds ratio [OR] 13.04; 95% CI 6.73–25.30; p<0.001), sex (men vs. women, OR 2.02; 95% CI 1.17–3.47; p = 0.01) and the ethnic group (Bantus vs. pygmies, OR 10.98; 95% CI 1.31–92.42; p = 0.03). In contrast, the HIV seroprevalence was higher in women than in men (OR 10.22; 95% CI 3.19–32.80; p<0.001). No specific risk factors were found in men, whereas women who were unmarried (OR 6.49; CI 2.45–17.17; p<0.001) or school-educated (OR 7.12; 95% CI 1.59–31.78; p = 0.01), or those with a history of sexually transmitted infections (OR 2.92; 95% CI 1.08–7.89; p = 0.03) had higher rates than other women.
Figure

Seroprevalence rates of hepatitis C virus (HCV) and HIV infection by sex and age in the general population of southern Cameroon, 2001.

Seroprevalence rates of hepatitis C virus (HCV) and HIV infection by sex and age in the general population of southern Cameroon, 2001. HIV/HCV coinfection is therefore rare in this general population, which lives in an area where both HCV and HIV are endemic. This finding could be related to the dissimilar epidemiologic patterns of the 2 infections. Indeed, HIV infection mainly affects young persons, especially young women, while HCV infection is more frequent in older persons of both sexes. We have previously postulated that HIV is likely to be transmitted by the sexual route, in a context of commercial logging and the extensive and complex sexual networks it induces (). In contrast, the route of HCV transmission is unclear. HCV seropositivity was not associated with a history of blood transfusion, injections, surgery, scarification, or tattooing. Intravenous drug use was not investigated in our study but was likely to be infrequent. Although sexual transmission could not be ruled out, especially between regular partners, the shape of the seroprevalence curves and the lack of association with HIV infection, syphilis, or other sexually transmitted infections suggests that this mode of transmission is inefficient, in keeping with other reports (,). Our seroprevalence curves and the study location are consistent with the hypothesis that frequent iatrogenic transmission occurred during mass medical campaigns conducted before 1960 (). The rate of HCV coinfection among the HIV-infected subjects in our study (8.6%) is much lower than the overall rate (25%–30%) in North America and Europe (,), where intravenous drug use is a major risk factor for both infections (,). This rate was even in the lower range of values found among HIV-infected heterosexual persons in industrialized countries (9%–27%) (). Our results therefore suggest that the high seroprevalence rates of HIV and HCV in Africa will not necessarily result in a high prevalence of HIV/HCV coinfection.
  9 in total

Review 1.  Chronic hepatitis C virus infection.

Authors:  Steven L Flamm
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

Review 2.  HIV/hepatitis C virus co-infection in drug users: risk behavior and prevention.

Authors:  Holly Hagan; Hanne Thiede; Don C Des Jarlais
Journal:  AIDS       Date:  2005-10       Impact factor: 4.177

3.  Hepatitis C virus infection in cameroon: A cohort-effect.

Authors:  Eric Nerrienet; Régis Pouillot; Guillaume Lachenal; Richard Njouom; Jermie Mfoupouendoun; Catherine Bilong; Philippe Mauclere; Christophe Pasquier; Ahidjo Ayouba
Journal:  J Med Virol       Date:  2005-06       Impact factor: 2.327

4.  Seroepidemiological survey of hepatitis C virus among commercial sex workers and pregnant women in Kinshasa, Democratic Republic of Congo.

Authors:  C Laurent; D Henzel; C Mulanga-Kabeya; G Maertens; B Larouzé; E Delaporte
Journal:  Int J Epidemiol       Date:  2001-08       Impact factor: 7.196

Review 5.  Epidemiology of viral hepatitis and HIV co-infection.

Authors:  Miriam J Alter
Journal:  J Hepatol       Date:  2005-11-21       Impact factor: 25.083

6.  Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London.

Authors:  A H Mohsen; S Murad; P J Easterbrook
Journal:  HIV Med       Date:  2005-05       Impact factor: 3.180

Review 7.  HIV and hepatitis C virus co-infection.

Authors:  Jürgen Kurt Rockstroh; Ulrich Spengler
Journal:  Lancet Infect Dis       Date:  2004-07       Impact factor: 25.071

Review 8.  Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa.

Authors:  Valsa Madhava; Christine Burgess; Ernest Drucker
Journal:  Lancet Infect Dis       Date:  2002-05       Impact factor: 25.071

9.  Commercial logging and HIV epidemic, rural Equatorial Africa.

Authors:  Christian Laurent; Anke Bourgeois; Mirelle Mpoudi; Christelle Butel; Martine Peeters; Eitel Mpoudi-Ngolé; Eric Delaporte
Journal:  Emerg Infect Dis       Date:  2004-11       Impact factor: 6.883

  9 in total
  7 in total

1.  Hepatitis C in Cameroon: What is the progress from 2001 to 2016?

Authors:  Borris Rosnay Tietcheu Galani; Richard Njouom; Paul Fewou Moundipa
Journal:  J Transl Int Med       Date:  2016-12-30

2.  Anti-HCV antibody among newly diagnosed HIV patients in Ughelli, a suburban area of Delta State Nigeria.

Authors:  Ogbodo Ekene Newton; Otue Akpevwe Oghene; Iheanyi Omezuruike Okonko
Journal:  Afr Health Sci       Date:  2015-09       Impact factor: 0.927

3.  Epidemiological profiles of human immunodeficiency virus and hepatitis C virus infections in Malian women: Risk factors and relevance of disparities.

Authors:  Nouhoum Bouare; Andre Gothot; Jean Delwaide; Sebastien Bontems; Dolores Vaira; Laurence Seidel; Paul Gerard; Christiane Gerard
Journal:  World J Hepatol       Date:  2013-04-27

Review 4.  Seroprevalence of hepatitis C virus infection in Cameroon: a systematic review and meta-analysis.

Authors:  Jean Joel Bigna; Marie A Amougou; Serra Lem Asangbeh; Angeladine Malaha Kenne; Jobert Richie Nansseu
Journal:  BMJ Open       Date:  2017-08-28       Impact factor: 2.692

5.  Prevalence of anti-hepatitis C antibodies and its co-infection with HIV in rural Cameroon.

Authors:  Valirie Ndip Agbor; Claude Tayou Tagny; Jules-Bertrand Kenmegne; Bih Awazi; Charlotte Ngansop; Dora Mbanya; Nicaise Ndembi
Journal:  BMC Res Notes       Date:  2018-07-11

6.  Prevalence and associated factors of Hepatitis C virus and human immunodeficiency virus infections among voluntary counseling and testing clients attending private health facilities in Bahir Dar city, North West Ethiopia 2014.

Authors:  Zena Ameha; Senait Tadesse; Abate Assefa; Belay Tessema
Journal:  BMC Res Notes       Date:  2019-10-25

7.  Intra-host diversity and evolution of hepatitis C virus endemic to Côte d'Ivoire.

Authors:  Joseph C Forbi; David S Campo; Michael A Purdy; Zoya E Dimitrova; Pavel Skums; Guo-liang Xia; Lili T Punkova; Lilia M Ganova-Raeva; Gilberto Vaughan; Yousr Ben-Ayed; William M Switzer; Yury E Khudyakov
Journal:  J Med Virol       Date:  2014-02-12       Impact factor: 2.327

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.